DR4 Antibody

Contact us
ProSci
Product Code: PSI-1167
Product Group: Primary Antibodies
Supplier: ProSci
CodeSizePrice
PSI-1167-0.02mg0.02mg£150.00
Quantity:
PSI-1167-0.1mg0.1mg£449.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species:
  • Human
  • Mouse
  • Rat
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Western Blot (WB)

Images

1 / 10
<strong>Figure 1 KO Validation in HeLa Cells</strong><br> Loading: 10 μg of HeLa WT cell lysates or DR4 KO cell lysates. Antibodies: DR4 1167 (1 μg/mL) and beta-actin 3779 (1 μg/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat Anti-Rabbit IgG HRP conjugate at 1:10000 dilution.
2 / 10
<strong>Figure 2 Independent Antibody Validation (IAV) via Protein Expression Profile in Cell Lines</strong><br> Loading: 15 μg of lysates per lane. Antibodies: DR4 1139 (1 μg/mL), DR4 1167 (4 μg/mL), beta-actin (1 μg/mL), and GAPDH (0.02 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
3 / 10
<strong>Figure 3 Western Blot Validation in Cell Lines</strong><br> Loading: 15 μg of cell lysates per lane. Antibodies: DR4 1167 (4μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
4 / 10
<strong>Figure 4 Immunofluorescence Validation of DR4 in HeLa Cells</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed HeLa cells labeling DR4 with 1167 at 5 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue). Image showing membrane staining on HeLa cells.
5 / 10
<strong>Figure 5 Immunocytochemistry Validation of DR4 in HeLa Cells</strong><br> Immunocytochemical analysis of HeLa cells using anti-DR4 antibody (1167) at 2 μg/ml. Cells was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
6 / 10
<strong>Figure 6 KD Validation in SW480 Cells (Goda et al., 2008) </strong><br> The expression of DR4 was knocked down via DR4 siRNA, 24 h later cells were treated with dipyridamole for 24 h. DR4 protein expression detected by anti-DR4 antibodies was disrupted. Dipyridamole up-regulated the expression of DR4.
7 / 10
<strong>Figure 7 Immunofluorescence Validation of DR4 in Rat Brain (Cantarella et al., 2014) </strong><br> DR4 protein expression detected by anti-DR4 antibodies was increased after transient brain ischemia (tMCAO) and decreased after pre-conditioning stimulus. Confocal microscopic images displaying NeuN (a,d, g) (green), DR4 (b, e, h) (red), and Merge (c, f, i) (yellow) in the brain peri-ischemic region of rats after 5 h.
8 / 10
<strong>Figure 8 Immunocytochemistry Validation of DR4 in Human Melanoma Cells (Ekmekcioglu et al., 2008) </strong><br> MeWo melanoma cells were exposed to affinity-purified MDA7/IL-24. After 48 h of treatment, cells were collected and cytospins prepared for cytochemical assessment of their TRAIL receptor (R1 and R2) expression (anti-DR4 or anti-DR5, AEC, hematoxylin). Both DR4 and DR5 expression were upregulated in MeWo cells after treatment.
9 / 10
<strong>Figure 9 Immunohistochemistry Validation of DR4 in Human Colon Tumors (Devetzi et al., 2016) </strong><br> DR4 expression in human colon tumors detected by anti-DR4 antibodies. Strong immunoreactivity is shown for DR4 in T167. Moderate immunoreactivity is shown for DR4 in T187.
10 / 10
<strong>Figure 10 KD Validation in HeLa Cells (Horinaka et al., 2005) </strong><br> HeLa cells were transfected with DR4 siRNA or LacZ control siRNA. At 24 h after transfection, the cells were treated with or without 20 μM luteolin for 24 h. Western blot analysis was carried out with anti-DR4 antibodies. DR4 expression was markedly reduced after DR4 knockdown.
❮❯

<strong>Figure 1 KO Validation in HeLa Cells</strong><br> Loading: 10 μg of HeLa WT cell lysates or DR4 KO cell lysates. Antibodies: DR4 1167 (1 μg/mL) and beta-actin 3779 (1 μg/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat Anti-Rabbit IgG HRP conjugate at 1:10000 dilution.
<strong>Figure 2 Independent Antibody Validation (IAV) via Protein Expression Profile in Cell Lines</strong><br> Loading: 15 μg of lysates per lane. Antibodies: DR4 1139 (1 μg/mL), DR4 1167 (4 μg/mL), beta-actin (1 μg/mL), and GAPDH (0.02 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
<strong>Figure 3 Western Blot Validation in Cell Lines</strong><br> Loading: 15 μg of cell lysates per lane. Antibodies: DR4 1167 (4μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
<strong>Figure 4 Immunofluorescence Validation of DR4 in HeLa Cells</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed HeLa cells labeling DR4 with 1167 at 5 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue). Image showing membrane staining on HeLa cells.
<strong>Figure 5 Immunocytochemistry Validation of DR4 in HeLa Cells</strong><br> Immunocytochemical analysis of HeLa cells using anti-DR4 antibody (1167) at 2 μg/ml. Cells was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
<strong>Figure 6 KD Validation in SW480 Cells (Goda et al., 2008) </strong><br> The expression of DR4 was knocked down via DR4 siRNA, 24 h later cells were treated with dipyridamole for 24 h. DR4 protein expression detected by anti-DR4 antibodies was disrupted. Dipyridamole up-regulated the expression of DR4.
<strong>Figure 7 Immunofluorescence Validation of DR4 in Rat Brain (Cantarella et al., 2014) </strong><br> DR4 protein expression detected by anti-DR4 antibodies was increased after transient brain ischemia (tMCAO) and decreased after pre-conditioning stimulus. Confocal microscopic images displaying NeuN (a,d, g) (green), DR4 (b, e, h) (red), and Merge (c, f, i) (yellow) in the brain peri-ischemic region of rats after 5 h.
<strong>Figure 8 Immunocytochemistry Validation of DR4 in Human Melanoma Cells (Ekmekcioglu et al., 2008) </strong><br> MeWo melanoma cells were exposed to affinity-purified MDA7/IL-24. After 48 h of treatment, cells were collected and cytospins prepared for cytochemical assessment of their TRAIL receptor (R1 and R2) expression (anti-DR4 or anti-DR5, AEC, hematoxylin). Both DR4 and DR5 expression were upregulated in MeWo cells after treatment.
<strong>Figure 9 Immunohistochemistry Validation of DR4 in Human Colon Tumors (Devetzi et al., 2016) </strong><br> DR4 expression in human colon tumors detected by anti-DR4 antibodies. Strong immunoreactivity is shown for DR4 in T167. Moderate immunoreactivity is shown for DR4 in T187.
<strong>Figure 10 KD Validation in HeLa Cells (Horinaka et al., 2005) </strong><br> HeLa cells were transfected with DR4 siRNA or LacZ control siRNA. At 24 h after transfection, the cells were treated with or without 20 μM luteolin for 24 h. Western blot analysis was carried out with anti-DR4 antibodies. DR4 expression was markedly reduced after DR4 knockdown.

Documents

Further Information

Additional Names:
DR4 Antibody: DR4, APO2, CD261, TRAILR1, TRAILR-1, DR4, Tumor necrosis factor receptor superfamily member 10A, Death receptor 4, TRAIL receptor 1
Application Note:
WB: 1-4 μg/mL; ICC: 2 μg/mL; IF: 5 μg/mL.

Antibody validated: Western Blot in human and mouse samples; Immunocytochemistry in human samples and Immunofluorescence in human and rat samples. All other applications and species not yet tested.
Background:
DR4 Antibody: Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel death domain containing receptor was recently identified and designated DR4 (for death receptor 4). The ligand for this novel death receptor has been identified and termed TRAIL, which is a new member in the TNF family. DR4 is also called TRAIL receptor-1 (TRAIL-R1). DR4 is expressed in most of human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. Like TNFR1, Fas and DR3, DR4 mediates apoptosis and NF-κB activation in many tissues and cells.
Background References:
  • Pan et al. Science 1997;276:111-3
  • Wiley et al. Immunity 1995; 3:673-82
  • Pitti et al. J. Biol. Chem. 1996;271:12687-90
  • Schneider et al. Immunity 1997; 7:831-6
Buffer:
DR4 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/ml
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Anti-DR4 antibody (1167) was raised against a peptide corresponding to 20 amino acids near the amino terminus of human DR4.

The immunogen is located within the first 50 amino acids of DR4.
ISOFORMS:
Human DR4 has only 1 isoform (468aa, 50kD).
NCBI Gene ID #:
8797
NCBI Official Name:
tumor necrosis factor receptor superfamily, member 10a
NCBI Official Symbol:
TNFRSF10A
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 50kD

Observed: 55kD (Post-modification: 1 N-linked glycosylation)
Protein Accession #:
AAC51226
Protein GI Number:
1945072
Purification:
DR4 Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis
SPECIFICITY:
DR4 antibody has no cross reaction to DR5.
Swissprot #:
O00220
User NOte:
Optimal dilutions for each application to be determined by the researcher.
VALIDATION:

KO Validation (Figure 1): Anti-DR4 antibodies (1167) specificity was further verified by DR4 specific knockout cell lysate. DR4 signal was detected in wild type cells, but not in the DR4 knockout cells.

Independent Antibody Validation in Cell lines (Figure 2) shows similar DR4 expression profile in human cell lines detected by two independent anti-DR4 antibodies that recognize different epitopes, 1139 against C-terminus domain and 1167 against the N-terminus domain.  DR4 proteins are detected in all the tested cell lines except CaCo-2 at different expression levels by the two independent antibodies.

KD validation (Figure 6, 10): Anti-DR4 antibody specificity was further verified by DR4 specific siRNA knockdown. DR4 signal in SW480 and HeLa cells transfected with DR4 siRNAs was disrupted in comparison with that in cells transfected with control siRNAs.

References

  1. Goda et al. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene. 2008 ;27(24):3435-45. PMID: 18193086
  2. Cantarella et al. Ischemic tolerance modulates TRAIL expression and its receptors and generates a neuroprotected phenotype. Cell Death Dis. 2014 ;5:e1331. PMID: 25032854
  3. Ekmekcioglu et al. Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathwaysvia MDA-7/IL-24. Cytokine. 2008;43(1):34-44.PMID: 18511292
  4. Devetzi et al. Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer. Sci Rep. 2016;6:36532. PMID: 27827395
  5. Horinaka et al. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene. 2005;24(48):7180-9. PMID: 16007131
  6. Malhi et al. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut. 2007;56(8):1124-31. PMID: 17470478
  7. Kalan et al. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors. Cell Rep. 2017;21(2):467-48 PMID: 29020632
  8. Kurita et al. GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis. Oncogene. 2010;29(34):4848-58.PMID: 20562908
  9. Potu et al. Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway. Oncotarget. 2014;5(14):5559-69. PMID: 24980819
  10. Ashley et al. In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. Br J Cancer. 2008;99(2):294-304. PMID: 18594532
  11. Cazanave et al. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem. 2011;286(45): 39336-48. PMID: 21941003
  12. Song et al. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008;283(36):25003-13.PMID: 18599488
  13. Yoo et al. Effect of hyperthermia on TRAIL-induced apoptotic death in human colon cancer cells: development of a novel strategy for regional therapy. J Cell Biochem. 2007;101(3):619-30. PMID: 17212362
  14. Lauricella et al. SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells. Biochimie. 2012;94(2):287-99. PMID: 21835222
  15. Cantarella et al. Protective effects of the sigma agonist Pre-084 in the rat retina. Br J Ophthalmol. 2007;91(10):1382-4. PMID: 17522150

Related Products

Product NameProduct CodeSupplier 
DR4 Peptide PSI-1167PProSci Summary Details